#Cabozantinib is active after contemporary IO combo in mRCC (ICR analysis, strict 2nd line):
👉 ORR 41% after IO-IO, PFS: 10.9 mo
👉 ORR 28% after TKI-IO, PFS 8.3 mo
👉 supports its use after IO combinations
doi.org/10.1016/j.eu...

📢 Accumulating administrative burdens place clinical trial at risk
🤝 as medical societies and patient advocates we formed the cross-disciplinary Coalition for Reducing Bureaucracy in Clinical Trials.
➡️ Read the Coalition’s 2025 Recommendations here:
bureaucracyincts.eu/coalition-re...

#SUNNIFORECAST - 1st study to compare IPI-NIVO vs. SOC (TKI or TKI-IO) in nccRCC entities

👍 central pathology
👍 better 1y-OS rate with IPI-NIVO
👍 best effect in CPS>1 pts.
🤔 no log-rank analysis
🤔 majority received TKI as SOC

👉 confirmed role of IO in nccRCC subtypes

doi.org/10.1016/j.an...

German RW cohort of LEN+PEM in #mRCC pts by @RamonaStellmach of the #GUARDIANS network

👉 therapy modifications are frequent in RW-cohorts
👉 includes pts. who are not trial-eligible
👉 confirms efficacy in broader population
👉 supports the use of LEN-PEM in RW setting

doi.org/10.1016/j.es...